Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omeros: 4Q Earnings Snapshot

03/01/2021 | 04:36pm EDT

SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $37.3 million in its fourth quarter.

The Seattle-based company said it had a loss of 60 cents per share. Losses, adjusted for non-recurring costs, were 54 cents per share.

The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 64 cents per share.

The drug developer posted revenue of $10.6 million in the period.

For the year, the company reported that its loss widened to $138.1 million, or $2.41 per share. Revenue was reported as $73.8 million.

Omeros shares have risen 36% since the beginning of the year. In the final minutes of trading on Monday, shares hit $19.41, a rise of 64% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OMER at https://www.zacks.com/ap/OMER

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about OMEROS CORPORATION
08/09OMEROS : Q2 Loss Narrows on Rising Revenue -- Stock Up 3% After-Hours
MT
08/09OMEROS : Q2 Earnings Snapshot
AQ
08/09OMEROS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
08/09OMEROS CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
08/09OMEROS CORPORATION : Reports Second Quarter 2021 Financial Results
BU
08/09Omeros Corporation Reports Earnings Results for the Second Quarter Ended June..
CI
08/03OMEROS CORPORATION : to Announce Second Quarter Financial Results on August 9, 2..
BU
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/16OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Financials (USD)
Sales 2021 112 M - -
Net income 2021 -122 M - -
Net Debt 2021 258 M - -
P/E ratio 2021 -8,34x
Yield 2021 -
Capitalization 999 M 999 M -
EV / Sales 2021 11,2x
EV / Sales 2022 6,98x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 15,98 $
Average target price 27,00 $
Spread / Average Target 69,0%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Ray Aspiri Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION11.87%999
BIONTECH SE340.60%90 003
GILEAD SCIENCES, INC.22.91%89 434
REGENERON PHARMACEUTICALS34.93%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.33%48 539